With the path to blockbusterland now in sight, Travere Therapeutics is ready to hit the ground running after Monday’s ...

A once-daily oral tablet, sparsentan is fully approved to reduce proteinuria in patients ages 8 and older with FSGS who do ...

Becoming the first and only fully FDA-approved treatment for focal segmental glomerulosclerosis (FSGS), Travere Therapeutics Inc.’s Filspari (sparsentan) has gained access to a second lucrative market ...

Recent health news highlights significant regulatory and technological advancements in the medical field. South Korea bans syringe stockpiling due to supply concerns amid the Iran conflict, while U.S.

Travere Therapeutics stock jumped early Tuesday after the FDA approved Filspari for a new kidney disease.

The clearance of Filspari in a condition known as FSGS ends a winding regulatory journey and unlocks a revenue opportunity ...

Nephrologists now have an approved treatment option for FSGS patients without nephrotic syndrome following the latest FDA ...

The US Food and Drug Administration has granted full approval to Sparsentan for the treatment of Focal Segmental ...

Full FDA approval establishes sparsentan as the first approved therapy for FSGS, addressing a longstanding reliance on ...

This is a developing news story. Please check back soon for updates. The FDA granted full approval to sparsentan for ...

The U.S. Food and Drug Administration (USFDA) has approved the expanded use of ​Travere Therapeutics' drug to treat a rare ...